logo

Tag : risk

Case: Content at a Small CRO

Carlton Hoyt 11:26 am , January 6, 2014

Content is an important sales support tool.It feels like every week I see or learn something that reinforces just how valuable content is to life science companies. For instance, I was recently discussing some sales dilemmas with the founder of a young, small CRO. Let’s call him Greg. Greg’s CRO performs a well-differentiated and valuable research service. However, Greg was lamenting about the “commoditization” of contract research – how his firm can’t seem to compete on quality and all anyone cares about is price.

Knowing what his CRO does, I was a bit disturbed by this. There are such things as commodities, sure, but the whole reason commodities become commoditized is because there is no difference in quality. Even coal fetches different prices based on, among other things, how clean it burns. If someone can mine better coal and get a better price for it, surely his CRO should be able to get a better price for their superior service. … I dug deeper.

Greg used a current problem he was having to illustrate his larger problem. He had drafted a proposal for his contact at a pharma company. That person reviewed his proposal, along with a number of others, then handed it to his boss to make a decision. According to Greg, the boss would then just choose one of the cheap ones.

Now there are times when budgets are tight and price is simply the most important factor, but this was a recurring problem. So what was really the big problem?

Greg’s CRO is young and small. He has built a rapport with his contact. He has not, however, built a rapport with the decision maker, which he does not have access to. So the person making the decision only knows Greg’s CRO from the information that is available about them on their website and with a quick internet search. This wouldn’t necessarily be a problem, but Greg’s CRO has no educational content. Unless the decision maker happens to know Greg or someone on his team, there is no reason for him to believe that they are capable of producing the higher-quality output they claim to be able to. Compared to the more established and lower cost CROs, selecting Greg’s CRO would be a high-risk endeavor!

To lower the perceived risk, and therefore increase the likelihood that their proposal is selected, Greg’s CRO needs to demonstrate their knowledge through content. Content can, at least to some extent, mitigate the inability to demonstrate knowledge through person-to-person content. It could help provide the confidence that may lack if Greg’s CRO cannot provide many reputable customer references. Instead of only knowing Greg’s CRO as a proposal, at least they would be able to build some degree of positive brand image.

Content is an extremely multifunctional marketing tool that can assist organizations in numerous ways. Content can aid in sales support, as with the case of this CRO, it can generate leads, it can help drive inbound search traffic, it can improve your brand. There’s so much that content can do, and it contributes to so many aspects of marketing, that content marketing should really be a default. Especially in knowledge-intensive sectors like contract research and life science tools, content should be a centerpiece of the marketing effort for most companies. Content marketing is simply too valuable, and valuable in too many situations, to ignore.

What do you think?

What would you do if you were Greg? Would you invest in content marketing? Would you take another approach? Join the discussion on LinkedIn and share your thoughts.

Marketing of Life Science Tools & Services

"Is content the centerpiece of your marketing effort? If it’s not, or if you’re not sure what you need to do to craft high-value, multifunctional content, contact us. We’ll put you on the path to more leads, improved conversion, and more effective overall marketing – with content at the center."
Case Study / Content Marketing / Demand Generation 11:26 am , January 6, 2014

Small Steps

Carlton Hoyt 11:58 am , December 12, 2013

For better conversion, allow your customers to take smaller stepsIt’s enticing to try to close every prospect at the first opportunity. You can certainly rationalize doing so – you’re just trying to make the most of every opportunity, ASAP. Attempting to do so, however, can drive away your customers by forcing them to choose before they are ready to buy. While this may seem obvious in theory, life science marketers and salespeople routinely attempt to push their customers through their buying journey.

Your scientist-customers are risk-averse. If a customer isn’t sure that your product or service can perform the job they need it to perform, or if they don’t yet see that it is worth the price, they’ll view the purchase as being a high-risk endeavor. Asking a fresh prospect to make a purchase is a very big step for them – it involves a lot of risk since they are not yet certain about the utility and value of your product. The conversion of such a step would be very, very low.

To improve your conversion, you must allow your prospects to take smaller steps. Break up the buying journey into easily digestible chunks. For instance, a prospect whose email address you received from a conference may be sent an series of emails linked to various pieces of content. They may be invited to view a demo video, then subsequently given a demonstration. Perhaps after that there is a free trial, and only then would they be given the “hard sell”. This is merely an illustrative example, but one in which we have broken up one potentially huge step (visiting a booth at a conference → buying a product) into many smaller, less risky steps.

Marketers can also use these small steps in conjunction with marketing automation, CRM and / or analytics software to gain more insights into the customer. These insights may be subsequently fed to sales and / or used to help score the leads to help ensure that sales resources are deployed effectively.

Any buying journey can be broken up into an infinitesimal amount of steps, but we don’t want to make the buying journey too long by breaking it into an extremely large number of tiny steps – or, even worse, to decrease conversion by providing too many opportunities to drop out of the process. Additionally, not every product has the same amount of risk and will require the same amount of steps. Generally speaking, products which are more novel to the customer, products which are complicated, more expensive products, and products which are more central to the scientists’ research will carry more risk and therefore require more steps. So how do we know how many steps we might need? Consider the informational requirements of the average customer when making a purchasing decision and develop a content roadmap. This well help you determine the appropriate content which should be delivered, and the nature of the content should enlighten you as to the form it should take. Always allow the customer a direct path to purchase and contact high-quality leads directly to nudge them into making a decision.

One final note – the “small steps” notion does not apply only to the actual purchase. Asking a fresh prospect to give up a plethora of personal information right away will also lead to a low conversion. Ensure that you don’t place any obstructively large steps in your customer’s way.

"To put our expertise in demand generation to work for your life science company, contact BioBM. When we couple your great products and services with our expertise in demand generation, we’ll achieve great results."
Blog / Demand Generation 11:58 am , December 12, 2013

Reduce the Risk in Buying

Carlton Hoyt 11:22 am , November 21, 2012

Life science marketers often hold many simultaneous viewpoints on why customers purchase products. Frequently, the attributed reasons include a hodgepodge of quality, price, ease of use, suitability for their application, adoption by others, various performance metrics and many other reasons that may be general or product-specific. All that gets a bit confusing, and is a bit over-defined if you ask me. I prefer to start from one attribute and then elucidate from there: life scientists make purchasing decisions based on risk.

Considering the scientist as a purchasing decision-maker, risk has two main components: financial and utility. Financial risk can be represented as price, although a more accurate representation is total cost of ownership (TCOO). If a product is very expensive, that makes the purchase more risky since there will be less resources to devote to other important endeavors and also since there are more sunk costs if the product doesn’t perform to the customer’s expectations. Utility risk pertains to the product ability to perform the functions that it is expected to by the customer. In other words, from a customer-centric standpoint: “In my particular application(s), how likely is this product to meet my expectations?”

The risk-based view can answer a question that leaves a lot of companies scratching their heads: why free samples are used so infrequently. It’s common for life science consumables companies, especially smaller companies, to give out free samples when a product is first launched in order to get people to try it. Most often, unless the brand is highly trusted, free samples fail their purpose and are left unused on the shelf. This is because giving away the product only serves to reduce one of the two main components of risk: financial risk. It does nothing to mitigate utility risk.

What life science tools and services companies should aim to do is reduce overall risk by lowering utility risk as much as possible such that financial risk does not need to be reduced and they therefore do not need to discount their product (or perhaps can raise the price on their product!) This gets to the heart of conveying value to the customer – that value should, as much as possible, be something that is experienced rather than something that is simply told. This becomes clear if you ask yourself: “What can we do to minimize utility risk?” Simply claiming that your product works would be pretty far down the list.

If you’re still not convinced, go out and ask a few scientists which of the following they would be more likely to purchase: 1) a product that claims to have better performance but you are unsure if it will work for you, or 2) a product that has lesser performance but you are certain it will work.

Performance metrics are undeniably important, and scientists have different reasons for purchasing different products. At the end of the day, the product with the lowest risk will be able to capture a greater market share than its competition.

"Looking for more insights on how your life science company can capture market share and accelerate revenue growth through improved marketing? Talk to BioBM. Our life science marketing experts can help your company identify opportunities, develop strategies to capitalize on them, and execute activities to capture value from them."
Blog / Demand Generation 11:22 am , November 21, 2012

Product Lines: Breadth or Depth

Carlton Hoyt 9:25 am , February 1, 2012

Should your life science tools company focus on breadth or depth in your product portfolio?Life science tools companies are constantly making important product development decisions, and almost all of these decisions involve making a tradeoff. Should your company focus its limited product development resources on entirely new lines, expansions to existing lines, or improvements to existing products? Much of this decision-making, especially for smaller companies, boils down to choosing between breadth and depth in the product portfolio. So what are the benefits of each, and when should each be given focus?

It’s certainly no easy question to answer generally. Without question much of the answer will depend on a company’s positioning and the opportunities that present themselves (a SWOT analysis is often good for helping to make such a determination), however there are many considerations that are less variable and can be discussed in a more general context. Let’s discuss a few of those.

Risk / Reward

To an extent, the 80/20 rule, or at the very least the rule of diminishing returns, comes into play in product development. A few key, highly differentiated products in any area are likely to make “80%” of your revenues in that area, assuming that you have such a product to begin with. Expanding on products in that area, or continuing to build on that key product through features, etc., will produce a far lesser return than did the development of the original product. Indeed, as more and more features are added to the key products, or more and more related products are added to the related product line, each improvement or addition will likely capture fewer and fewer customers. If the opportunity exists to build a disruptive product in another market, that will generally offer a much greater opportunity to build sales.

The risk of expanding into new markets, however, is much greater. Developing an entirely new product often involves the development or acquisition of new technology, and the cost is often much greater. It will involve markets that your company is less familiar with, and you may misjudge the market. Customers also gravitate towards holistic solutions, and if your offering doesn’t have the product support within your own line to stand alone, that may be viewed with significant negativity. Additionally, and this will lead us into the next point of discussion, if you don’t have a strong focus in any area then your company’s brand won’t be recognized as an authority in any area.

Having too narrow of a product line is a risk in and of itself as well. If you’re entirely invested in one market, and a competitor brings a highly disruptive technology into that market, you could be out of business. While building around a highly successful product line may be seen as risk-averse, small companies with limited product development resources still need to diversify to some extent.

Branding

If you have many great but unrelated ideas, continuously going after the “80%” may seem very tempting, but it does have its drawbacks. Not being known for any one area could have negative effects on your company’s brand. Especially if customers in a market have varied needs, you won’t be known as a go-to source for any of the types of products that you offer, even if you have that one standout product. If your product line is all over the place, having disparate, eclectic products with having a well-rounded offering for any particular need, customers won’t think to look to your company for anything, and that can certainly be problematic.

On the other hand, having a deep product line can help establish you in that area, again assuming your products are sufficiently differentiated. It also helps you focus brand-building marketing efforts, or at the very least makes them easier.

It’s worth repeating that there is no right answer or formula to follow that will tell you where you should focus your product development efforts. The decision must be dependent on your situation, risk tolerance, opportunities, and more. Align your company’s product development goals with your overall goals, carefully analyze your situation, and you’ll know what the right decision is.

"Are your product development efforts producing the results your life science company wants? Is your pipeline optimally aligned to deliver on future goals? Cut out the guesswork. Call BioBM Consulting and we’ll make sure your product development gives you the best opportunity to succeed."
Blog / Branding / Marketing Strategy 9:25 am , February 1, 2012

Slowing Global Economy

Carlton Hoyt 10:16 am , September 29, 2011

Image courtesy of ponsulak and FreeDigitalPhotos.net.You see it on the television, you read it in the newspapers – the global economy is slowing. The IMF has cut GDP estimates for the world as a whole to 4.0%, highlights the threat of renewed recession in the US and EU, has curbed estimates on China slightly, and projects a sharp drop-off in India’s economic growth compared to last year. Other economies are projected to show sharply weaker growth as well. Huge public debts also threaten austerity in major economies. All in all, the global economy is in a very precarious position … but what does that mean for you, the manufacturers and distributors of life science research tools?

Overall, the global life sciences research market will likely contract, and we are already seeing supporting evidence of such. The proposed 2012 NIH budget is trimmed by a modest 0.6%. I expect European and Japanese life science R&D spending to be trimmed by a similar amount. While many developed economies are struggling with debt, investments in research don’t seem to be high-priority chopping block items. What about the massive $100bn+ pharmaceutical and biotech research and development budgets? Well, while one may reasonably postulate that people in developed economies are losing their health care along with their jobs and this would lead to falling revenues, that does not seem to be the case. In fact, the largest threat to pharma / biotech seems to be generics, but even then global sales growth is still projected to be positive, albeit diminished. That being the case, don’t expect private-sector R&D to grow, but it shouldn’t shrink either. Overall, we will likely see only a very modest contraction in overall life science R&D spending. That’s good news.

The bad news is that this cuts the “growth” out of the market, although this is worse news if you’re a large company or an established player in your market segment. These companies rely more on growth in the market in order to grow themselves (at least organically), and companies with a high market share or those that have seen their market share plateau are more likely to see a sales contraction from a contraction in global life science R&D funding. Smaller companies that have plateaued will need to assess their technology and competencies in order to develop plans for value-added innovation in current markets and / or expansion into new markets in order to sustain growth, or else they will simply contract with the market. Larger companies with more cash will likely use M&A to achieve growth. Look for them to acquire early-stage companies with very promising high-impact technologies as well as established small-to-mid size companies that have high-quality product lines that are complimentary to their own.

Contrary to general consumer behavior, we are unlikely to see a move to lower-cost products within the research tools market. Less research funding generally means less labs or smaller labs, not across-the-board cuts in funding to all labs. In other words, the dollars spent per researcher will likely be roughly the same, but the overall number of researchers will decrease, spreading the contractile pressure fairly evenly across all laboratory products instead of driving researchers to lower-cost products. Practically speaking, this means that manufacturers and distributors who sell products that compete on price will feel the squeeze just as bad, if not worse since many of these “generic” or “commodity” type manufacturers do not have the technology and R&D capability to expand into new markets. As these companies have thin margins and already focus on efficiency, thereby not leaving much more room to squeeze out additional efficiency, they will feel the pain of any contraction quite acutely if they haven’t been saving cash.

On the other hand, small and mid-size companies that rely more heavily on technology adoption for growth will likely still have strong performance, as companies will still want to put their research dollars into tools that make research faster, better, and easier. These companies don’t rely so much on market growth since they are, in effect, building sub-markets and carving out new space. While their effective “ceiling” may be decreased, this will likely affect them only minimally since they are still in the growth phase and have not come close to reaching their maximum potential. One exception to this could be those companies that manufacture high-value capital equipment that is most often purchased to upgrade from an older instrument and / or technology. Look for sales in these products to decline somewhat as organizations look to decrease their R&D overhead by decreasing funding to core facilities and putting off large, non-critical purchases. With few exceptions, however, scientists will continue to adopt new technologies.

Another way a contraction will affect the life science research tools market is by decreasing marketing ROI. With an overall decrease in spending, there will be more marketing dollars chasing fewer customers, so marketing ROI will likely decrease by a few percentage points, especially since new players in the market will likely continue to enter given its size and comparative stability, and also to seize opportunities created by new technologies. While sales forces can shrink to demand, the channels through which marketers need to reach customers do not shrink, and this puts a fairly strict limit on how much a marketing budget can contract without negatively affecting sales.

A contracting global economy certainly will not effect the research products markets as much as it will the consumer markets, and this is very good news for those in the space and for the future of biomedical research a a whole. Nevertheless, any slowing or contraction presents risks. By understanding the situation and the likelihood of future possibilities and preparing for what may lie ahead, life science companies can plan for and mitigate those risks to help ensure continued success.

"Are you ready for a contraction or other market disruptions? With a troubled global economy, now is as good a time as any to plan for scenarios which may negatively impact your life science business. If you’re not sure of how you can protect yourself from downside risk, ask the experts at BioBM Consulting. Our business consultants can help you develop a strategy and plans-of-action that will cushion your company from macroeconomic hardships beyond your control."
Blog / Marketing Strategy 10:16 am , September 29, 2011

Acting With Confidence

Carlton Hoyt 1:01 pm , February 27, 2011

Life science market research will hep you understand your target market and reduce risk.Small life science companies are surrounded by uncertainty. How can we improve our service to customers? What new product would be of greatest interest to scientists? How can we be more certain that our strategic direction is in sync with future realities? What can we do to add value to our products? How can we attract new segments of the market? All of these are almost constant questions among all companies, but small companies are the most likely to leave them unanswered or do an insufficient amount of research to confidently answer them. Especially in rapidly changing markets such as the market for laboratory products and services, having solid information on which to base your company’s actions is highly important.

The Importance of Good Information

“I love talking about nothing. It is the only thing I know anything about.” – Oscar Wilde

All businesses need to understand the potential risks and rewards of any specific course of action. Beyond being a principal tenet of the practice of risk reduction, it is essentially a core business need. Businesses act on this basis. If the expected reward from a specific course of action will result in a return that justifies the amount of risk, then this action is taken. But how do you even know the risks or rewards of a hypothetical future action? … The answer? Market research. Market research provides the information that allows the quantification of uncertainty and risk.

For example, say a company that develops and sells cell lines for research purposes is considering which of a choice of new cell lines to commercialize. Without appropriate information, the choice would effectively be a poorly educated guess. Even if the company has the experience to “feel out” where the demand lies, they will be acting on a short-sighted intuition with little information to justify it. One cell line may be in more demand today, but the market for it may be shrinking while another is growing, and therefore another may have greater demand in the future and provide a better return over the lifetime of the product.

With a well-designed study, almost any question about the market can be answered, and the information discovered can be extremely valuable in reducing risk and uncertainty and maximizing returns.

Types of Market Research

“Be curious always, for knowledge will not acquire you; you must acquire it.” – Sudie Back

Market research can be segmented into two distinct types: secondary research, and primary research. Secondary research utilizes information that already exists. This may consist of mining databases, utilizing demographical data, analyzing existing research reports, etc. Primary market research involves reaching out directly to individuals within the target market. Primary market research can be in person, online, or via any other mode of communication, and may involve interviewing, surveying, questionnaires, etc. Either type may be quantitative or qualitative, although secondary market research is almost always quantitative.

Making Market Research Work for You

“Knowledge is of no value unless you put it into practice.” – Anton Chekhov

The first issue of importance when conducting life science market research, and one that you will have a large part in answering, is understanding what you want answered and who should be providing the answers. What information is it that you are looking to collect? Will this information answer the question you have in mind? Will answering that question help you reduce uncertainty in ways that are relevant to your business needs? Who should be answering this question to make the answer relevant? Would there be a subset of life scientists who would best answer the question, or maybe lab managers, or perhaps even distributors? These questions need to be answered to ensure the relevance of the market research study.

The next issue is the study design. How should the information be collected. Would secondary or primary research be most appropriate (or a combination of both)? How important is the question? Do you need a very thorough, and therefore more expensive, study or would a less thorough or less structured study be sufficient? How should the data be collected and analyzed?

The last and most important issue is using the data! No matter how much market research you do, it’s not going to help you unless you apply the information to help guide your decision-making.

The life sciences are rapidly evolving and in a near constant state of change, and uncertainty and risk are abound because of it. Utilizing properly designed and executed market research can give your life science company a more certain future, improved returns, and the ability to act with confidence.

"Is your company facing an important decision that you would like more information to make? Are you worried that too much uncertainty is clouding your view of the future? BioBM’s life science business and marketing consultants can design and execute a market research study to fit your needs and your budget and help you regain your confidence. We are experienced in small and large-scale studies and will tailor a custom solution to your life science company’s unique needs. Talk to us and we can discuss how we can leverage market research to help you remove uncertainty and minimize risk."
Blog / Market Research 1:01 pm , February 27, 2011